She is one of famous Actor with the age 38 years old group. Born on Februin South Korea, Lee Min-jung started her career as Actor. Lee Min-jung, better known by her family name Lee Min-jung, is a popular South Korean Actor. First NameĬheongdam-dong, Gangnam, Seoul, South Korea Instagram, Facebook, Twitter and much more. Learn How much net worth Lee is in this year and how she spend her expenses? Also learn about how she is rich at the age of 49 years old? also know about her Social media accounts i.e. After successful completion of phase I/II single-center study, three-drug, durvalumab in combination with olaparib and cediranib, is currently being investigated in the multi-center phase II trial (NRG-GY023) for platinum-resistant ovarian cancer.Discover Lee Min-jung‘s Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Using fresh tissue and blood samples, her correlative studies identified that upregulation of VEGF signaling was associated with a lack of response to PD-L1 inhibitor and PARPi combination, indicating the importance of blocking VEGF/VEFGR signaling in ovarian cancer. Lee’s work is the first demonstration of safety and early activity of PD-L1 blockade with a PARPi, olaparib, and/or a VEGFR inhibitor, cediranib. Clinical and translational investigation of PARPi-based combinations in HGSOC.ĭata suggest that inhibition of DNA repair and angiogenesis pathways modulate the immune response by increasing DNA damage and attenuating the immunosuppressive microenvironment. Ongoing work is focused on mechanical investigation of replication stress response and resistance to the drugs, and its biological relevance in ovarian cancer. Lee proposes that high levels of replication stress define a subgroup of PARPi-resistant HGSOC susceptible to therapeutic targeting of this pathway. Her laboratory also identified unique mechanisms of PARPi-resistance in HGSOC cell lines based on the treatment dosing and schedules which provide invaluable resources for the development of novel clinical trials and translational studies. Lee’s laboratory has begun to characterize ATR/CHK1 pathway blockade resistant HGSOC using preclinical models and clinical samples. Characterization of resistance to DNA repair inhibitors.ĭr. These studies incorporate the collection of patient tissue and blood samples to understand the biology and resistance to the drugs, and to develop the next generation of clinical trials. Lee also has begun to investigate the ATR/CHK1 pathway inhibition in PARP inhibitor (PARPi)-resistant HGSOC and designed new clinical trials of ATR/CHK1 pathway blockade-based combinations for PARPi-resistant HGSOC. Lee demonstrated the early clinical activity of CHK1 inhibitor (CHK1i) in heavily pretreated HGSOC which is currently being tested in a multi-center clinical trial. Clinical and translational investigation of ATR/CHK1 pathway blockade in HGSOC.ĭr. Lee’s group studies clinical and translational aspects of modulating these proteins and their interactions with other pathways in HGSOC to develop novel clinical trials. Lee demonstrated augmenting replication stress by modulating ATR/CHK1 pathway would induce DNA damage and cell death in various HGSOC preclinical models. ATR and CHK1 function as primary mediators of G2/M cell cycle arrest in tumors with p53 mutation and associated G1/S cell cycle dysregulation, such as high-grade serous ovarian cancer (HGSOC). Replication stress as a novel therapeutic strategy.Ĭell cycle checkpoints such as ATR and CHK1 are the major regulators of DNA replication and DNA damage repair. Lee’s group investigates the therapeutic potential of targeting key proteins of DNA damage response and replication stress in ovarian cancer.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |